The National Cardiovascular Data Registry (NCDR)-CathPCI Registry is the largest ongoing registry of PCI in the United States, Background-Acute kidney injury (AKI) complicating percutaneous coronary intervention (PCI) is associated with adverse clinical outcomes. To date, no studies have evaluated the association of blood transfusion with AKI in patients undergoing PCI. Methods and Results-We used a retrospective cohort study of all patients with acute coronary syndrome undergoing PCI from CathPCI Registry (n=1 756 864). The primary outcome was AKI defined as the rise in serum creatinine post procedure ≥0.5 mg/dL or ≥25% above baseline values. AKI developed in 9.0% of study sample. Patients with AKI were older, more often women, and had high prevalence of comorbidities, including diabetes mellitus, hypertension, and advanced stages of chronic kidney disease at baseline. Blood transfusion was utilized in 2.2% of patients. In the overall sample, AKI developed in 35.1% of patients who received transfusion versus 8.4% of patients without transfusion (adjusted odds ratio, 4.87 [4.71-5.04]). In the subgroup of patients who sustained bleeding event and received transfusion, the rate of AKI was significantly increased across all preprocedure hemoglobin levels versus no blood transfusion. Similar findings were seen in the subgroup of patients with no bleeding event. Conclusions-Blood transfusion is strongly associated with AKI in patients with acute coronary syndrome undergoing PCI. Further investigation is needed to determine whether a restrictive blood transfusion strategy might improve PCI outcomes by reducing the risk of AKI. (Circ Cardiovasc Interv. 2016;9:e003279.
A cute kidney injury (AKI) is one of the most common adverse events after percutaneous coronary intervention (PCI) and is of prognostic significance. 1, 2 Risk factors for its development have been the focus of multiple studies, and several patient-related and procedure-related factors have been identified. 3, 4 However, no prior studies have considered the risks of periprocedural blood transfusion.
There are many pathophysiological mechanisms by which blood transfusion might cause AKI, which are mainly related to impaired tissue oxygen delivery, and inflammation and oxidative stress. 5 Recently, blood transfusion has been identified as a risk factor for AKI in cardiac surgery 5, 6 and in transcatheter aortic valve replacement. 7 Patients undergoing PCI are prone to bleeding given the invasive nature of the procedure and the use of antithrombotic and antiplatelet agents. Transfusion is relatively commonly used in these patients, and there is considerable variation in blood transfusion practices among patients undergoing PCI at the US hospitals. 8 The appropriate use of transfusion in this patient population might be influenced by its effect on AKI.
Anemia is well-recognized as a risk factor for AKI, 9 and recently periprocedural bleeding in PCI patients was also identified to be associated with AKI. 10 However, the relationship between anemia, bleeding, and transfusion and the risk of AKI has not been well studied. Further characterization of this relationship and definition of other risk factors might help broaden prophylactic strategies against post-PCI AKI.
In this cohort of patients with acute coronary syndrome (ACS) who underwent PCI, we aimed to (1) assess the association of blood transfusion with AKI and (2) characterize this relationship with anemia and bleeding. Blood Transfusion and Acute Kidney Injury the details of which have been preciously published. 11 It is cosponsored by the American College of Cardiology Foundation and the Society for Cardiovascular Angiography and Interventions and collects data on patient and hospital characteristics, clinical presentation, procedural characteristics, and in-hospital outcomes for PCI procedures from >1500 sites across the United States. Data are entered into NCDR-certified software at participating institutions. Comprehensive data quality programs are implemented, including data quality report specifications for data capture and transmission and an auditing program. 12 An NCDR committee prospectively defines the variables and is available at NCDR website (http://www.ncdr.com).
The study was approved by the institutional review board of Duke University Medical Center, which determined that the study met the definition of research not requiring informed consent.
For this study, we identified all NCDR patients admitted with ACS and undergoing a PCI between July 1, 2009, and June 30, 2014 (n=2 388 833). Patients with the following missing information were excluded: preprocedure and peak postprocedure in-hospital serum creatinine level (n=368 769; 15.4%), preprocedure hemoglobin (n=32 881; 1.4%), and missing data on blood transfusion (n=792; 0.03%). Patients with cardiogenic shock within 24 hours or at the start of PCI (n=36 283; 1.5%); cardiac arrest within 24 hours (n=37 044; 1.6%); deaths within 24 hours (n=45 710; 1.9%); salvage patients (n=5 338; 0.2%); patients undergoing multiple PCIs during a single hospitalization (n= 58 372; 2.4%); and patients currently on dialysis at the time of their PCI (n=45 568; 1.9%) were also excluded. The final analytic cohort included n=1 756 864 patients.
Outcomes and Definitions
The primary outcome was AKI. AKI was defined, as in prior studies, as an increase in serum creatinine post PCI ≥0.5 mg/dL or ≥25% above baseline values. The definitions used for transfusion, bleeding complications, vascular complications, and in-hospital events (myocardial infarction, congestive heart failure, cardiogenic shock, stroke, tamponade, and death) are taken from the CathPCI data collection form, version 4.4. 13 Major bleeding was defined as any of the following occurring within 72 hours after PCI or before hospital discharge (whichever occurs first): site-reported arterial access site bleeding, which may be either external or a hematoma >10 cm for femoral access, >5 cm for brachial access, or >2 cm for radial access; retroperitoneal, gastrointestinal, or genitourinary bleeding; intracranial hemorrhage; cardiac tamponade; postprocedure hemoglobin decrease of 3 g/dL in patients with a preprocedure hemoglobin level ≤16 g/dL; or postprocedure nonbypass surgery-related blood transfusion for patients with a preprocedure hemoglobin level ≥8 g/dL. 14
Statistical Analysis
Patients were stratified by the presence of AKI after PCI. Continuous variables are expressed as median with interquartile range and were compared by the Wilcoxon rank-sum test; categorical variables are expressed as counts with proportions and were compared using Pearson χ 2 test.
After the raw event rates were calculated, we examined the association between blood transfusion and AKI. A multivariable logistic regression was used to estimate the marginal effects of blood transfusion. The Generalized Estimating Equation method with exchangeable working correlation structure was used to account for within-hospital clustering, because patients at the same hospital are more likely to be transfused at similar rates (ie, within-center correlation for response). Variables included in the model were age, preprocedure creatinine, prior cerebrovascular disease, prior heart failure, diabetes mellitus, anemia (hemoglobin <10 mg/dL), weeks HF, intraaortic balloon pump before procedure, and contrast volume, based on previously developed CathPCI registry models for post-PCI AKI. 4, 15 The unadjusted and adjusted odds ratios (ORs) of the association of blood transfusion with AKI for the overall sample and the subgroups (ST-segment-elevation myocardial infarction, and unstable angina/non-ST-segment-elevation myocardial infarction ) are presented. In addition, analysis was performed to determine the association between blood transfusion and AKI among patients who did or did not have reported postprocedure bleeding events.
We also examined whether drop in hemoglobin is independently associated with AKI. Patients were divided into 4 groups according to the change in hemoglobin before and after post-PCI procedure: group A-no decrease in hemoglobin or decreased hemoglobin <1 g/ dL; group B-decreased hemoglobin from 1 to <2 g/dL; group Cdecreased hemoglobin from 2 to <3 g/dL; and group D-hemoglobin decrease ≥3 g/dL. The covariates in the adjusted models are the same as the ones used for the analysis of blood transfusion and AKI but excludes anemia. The Generalized Estimating Equation model was run to get unadjusted and adjusted OR for AKI versus no AKI for each group (using group A as reference).
To determine whether bleeding events were associated with transfusion and AKI, the study sample was stratified by preprocedure hemoglobin (g/dL; ≤10, >10 to ≤13, >13 to ≤15, and >15 g/dL). We determined the relationship between preprocedure hemoglobin, transfusion, and AKI, and unadjusted and adjusted ORs were reported for the overall sample and in addition for the prespecified subgroups (major bleeding cohort and no bleeding cohort). The 3-way interaction (transfusion by bleeding by baseline hemoglobin level) was tested.
As a sensitivity analysis, a propensity analysis was performed matching nontransfusion to transfusion patients. First, we fit a logistic regression model with transfusion as a response variable and bleeding (yes/no), hemoglobin, change in hemoglobin, and all the other adjustment variables as predictors. Splines of continuous variables were added to account for nonlinearity. Based on their propensity to receive a transfusion we matched 19 736 transfusion patients in a 1:1 fashion.
All analyses were performed by the Duke Clinical Research Institute using SAS version 9.2 (SAS Institute, Cary, NC).
Results

Baseline Characteristics
AKI developed in 157 386 patients (9.0%) of the 1 756 864 overall sample (Table 1) . Patients with AKI were older (66.0
WHAT IS KNOWN
• Acute kidney injury is one of the most common adverse events after percutaneous coronary intervention and is of prognostic significance.
• Several patient-related and procedure-related factors have been identified as risk factors for its development.
• Blood transfusion is relatively commonly used in these patients and there is considerable variation in blood transfusion practices among patients undergoing percutaneous coronary intervention at US hospitals.
WHAT THE STUDY ADDS
• In this retrospective study, we identified an independent association between blood transfusion and acute kidney injury in acute coronary syndrome patients undergoing percutaneous coronary intervention.
• This association was significant even among patients with anemia at baseline and who did subsequently sustain a bleeding event, suggesting that a restrictive blood transfusion policy needs to be further investigated for its potential to improve the safety of percutaneous coronary interventions. Blood Transfusion and Acute Kidney Injury versus 64.0 years; P<0.01), more likely women (43.2% versus 31.9%; P<0.01), and had a high prevalence of comorbidities including diabetes mellitus (46.1%) and hypertension (85.1%; all P<0.01). Around 24% of patients had chronic kidney disease at baseline (eGFR <60 mL/min per 1.73 m 2 ). Patients with AKI more often had advanced stages of chronic kidney disease (eGFR ≤45 mL/min per 1.73 m 2 ) at baseline (12.0% versus 8.5%; P<0.01). These patients also presented more often with ST-segment-elevation myocardial infarction or non-ST-segment-elevation myocardial infarction (57.4% versus 47.1%; P<0.01) and had congestive heart failure within 2 weeks of presentation (18.4% versus 9.1%; P<0.01). They more often underwent urgent or emergent cardiac catheterization (79.6% versus 71.8%; P<0.01), and the median contrast 
AKI and Risk of In-Hospital Adverse Events
Consistent with prior studies, we found that patients with AKI had worse in-hospital outcomes. Bleeding complications (4.5% versus 1.4%; P<0.01) and in-hospital adverse events (periprocedural myocardial infarction, cardiogenic shock, congestive heart failure, cerebrovascular accident, tamponade, and requirement for dialysis; 9.4% versus 3.0%; P<0.01) were more frequent in these patients ( Table 2 ).
Blood Transfusion Utilization
In the overall cohort, blood transfusion was given in 38 626 (2.2%) patients (Table 3 ). Blood transfusion was more likely to be utilized in patients with low hemoglobin (≤10 g/dL) at baseline (17.9%) and patients with bleeding (35.8%). However, there were a small percentage of patients who received transfusion despite normal hemoglobin levels at baseline and the absence of captured bleeding events (0.2%). In the overall sample, AKI developed in 35.1% patients who were given blood transfusion versus 8.4% patients with no blood transfusion (adjusted OR [95% confidence interval (CI)], 4.87 [4.71-5.04]).
Bleeding and Risk of AKI
A stepwise and significant positive association was observed between the severity of the drop in hemoglobin and AKI in our study population ( 
Blood Transfusion and Its Association With AKI as Based on Preprocedure Hemoglobin Level
The lower the baseline hemoglobin level, the higher the rate of AKI in the overall sample (hemoglobin ≤10, 19.0%; hemoglobin >10 to ≤13, 11.1%; hemoglobin >13 to ≤15, 7.6%; hemoglobin >15 g/dL, 6.6%; P value of the trend <0.01). There is a significant 3-way interaction transfusion by bleeding by preprocedure hemoglobin groups (P<0.001; Table 5 ). In the subgroup of patients who sustained a bleeding event and received blood transfusion, the rate of AKI is significantly increased across all the preprocedure hemoglobin levels versus patients who did not receive blood transfusion ( Table 5 ).
In the subgroup of patients who did not sustain a bleeding event and received blood transfusion, the rate of AKI is also significantly increased across all the preprocedure hemoglobin levels versus patients who did not receive blood transfusion ( Table 5 ).
In the propensity-matched analysis, the AKI rates among 19 736 transfusion patients and 19 736 nontransfusion patients are 34.3% and 23.2%, respectively. With pair as repeated measure, the association between transfusion and AKI persisted (1.73 [95% CI, 1.65-1.80]). Table 6 provides a comparative assessment of the strength of the association of transfusion and bleeding with the risk of AKI in comparison to previously identified preprocedural variables. In the cohorts of patients with anemia at baseline and without a postprocedure bleeding event or in patients without anemia at baseline but who did suffer a bleeding event, blood transfusion was the strongest predictor of AKI among all the other well recognized variables (adjusted OR [95% CI]: 2.79 [2.56-3.05] and 2.50 [2.39-2.60], respectively). In the overall cohort with anemia at baseline and who subsequently sustained a postprocedure major bleeding, blood transfusion was also independently associated with AKI (adjusted OR [95% CI]: 1.13 [1.07-1.20]).
Discussion
Blood transfusion is known to be associated with increased risk of adverse events including myocardial infarction, stroke, and in-hospital mortality in patients undergoing PCI. 8 In this study, we expand these findings to identify that blood transfusion is also independently associated with AKI in patients with ACS undergoing PCI. Almost 1 out of 3 patients who received blood transfusion developed AKI regardless of the baseline hemoglobin level or whether they sustained a bleeding event. The independent association of transfusion with AKI was significant even among patients with anemia at baseline and who did subsequently sustain a bleeding event. Bleeding was also identified to be independently associated with AKI, an association that correlated closely with the severity of bleeding. This association is more pronounced when bleeding is combined with transfusion. Our findings need to be further investigated to determine whether restrictive use of blood transfusion and whether practicing bleeding avoidance strategies would improve the safety and outcomes of PCI by decreasing the risk of AKI.
Our study is the first to investigate the association of blood transfusion and AKI in patients undergoing PCI. However, over the past decade, several studies have Blood Transfusion and Acute Kidney Injury identified an association between transfusion and AKI in other clinical settings including cardiac surgery patients 5, 6 and more recently after transcatheter aortic valve implantation. 7 The mechanisms by which transfusion could cause AKI have not been clearly defined, but several potential pathophysiological explanations are postulated. These are mostly related to impairment of tissue oxygen delivery and predisposition to inflammatory response and oxidative stress. During storage and in a time-dependent manner, red blood corpuscles undergo irreversible structural AKI indicates acute kidney injury; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CVA, cerebrovascular accident; GFR, glomerular filtration rate; IABP, intra-aortic balloon pump; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; and UA, unstable angina. Blood Transfusion and Acute Kidney Injury and functional changes including reduced deformability, increased aggregability, and diminished microvascular autoregulatory abilities all of which predispose to tissue hypoxia. 6, [16] [17] [18] The coadministration of toxic substances that accumulated in the storage supernatant including microparticles, lipophosphatidylcholines, cytokines, free hemoglobin, and iron may promote inflammatory response and oxidative stress and contribute to organ tissue dysfunction in transfused patients. [19] [20] [21] [22] [23] [24] AKI is a common adverse event after PCI and is associated with increased morbidity and mortality and health care costs. 1, 2, 4 Multiple independent predictors have been identified for the development of AKI in patients undergoing PCI, and recently risk models for predicting AKI after PCI have been developed and validated using the CathPCI data set. 4, 15 In our analysis, we expand on these findings by identifying blood transfusion and bleeding as other strong predictors of AKI in PCI patients. In a comparative assessment, we demonstrated that blood transfusion was the strongest predictor of AKI in patients with anemia at baseline and without a postprocedure bleeding event and in patients without anemia at baseline but who did suffer a bleeding event.
The association of transfusion with adverse events has been well studied including PCI patients. In previous analysis of CathPCI patients, transfusion was found to be associated with in-hospital myocardial infarction, stroke, and mortality. 8 It is also known that among patients undergoing PCI at US hospitals, there is considerable variation in blood transfusion practices. 8 In our current study, we did identify that the 2.2% of PCI patients who received blood transfusion are at an additional risk of developing AKI. Thus, greater efforts need to be implemented to first better define the population of patients in whom transfusion could be of benefit and also increase the awareness of the nonbenign nature of blood transfusion. The negative impact of bleeding on short-term and longterm outcomes of PCI has also been well established. It is now widely recognized that there is a stepwise increase in mortality as bleeding severity worsens. 25 More recently, the risk of AKI in PCI patients was identified to correlate with bleeding severity. 10 These findings are reproduced in our study; however, our study is unique in which we identified that this risk is valid even after adjustment for the utilization of blood transfusion. The relation between bleeding, blood transfusion, and AKI is complex and likely multifactorial. It has been reported that bleeding is related to AKI regardless of the hemodynamic changes that might be attributed to it. 10 It is postulated that hypovolemia, anemia, diminished oxygencarrying capacity, and systemic inflammation might lead to the adverse events associated with bleeding. However, blood transfusion could lead to paradoxical decrease in tissue oxygenation because of shifts in the oxyhemoglobin dissociation curve, increases in systemic inflammation, and the lack of nitric oxide in packed red cells. 22, 26, 27 All together, these could lead to AKI.
Limitations
This study has several limitations. First, given that the observational nature of data collected, it is possible that the observed relationships were influenced by unmeasured confounders, and thus causality cannot be inferred. Second, the number of blood units transfused is not available to analyze whether there is a stepwise relationship between volume blood transfusion and AKI. Third, the timing of blood transfusion in relation to PCI and the development of AKI could not be determined. Fourth, whether there is a level of hemoglobin below which transfusion would not be associated with AKI could not be inferred from our analysis. Fifth, the type of AKI could not be specifically determined. Sixth, there is a minority of patients who had normal hemoglobin level and did not sustain bleeding event, but still did receive blood transfusion. We think that this is likely related to data entry error. Finally, although serum Cr levels would likely be checked routinely after PCI in patients with ACS, some patients in whom increased serum creatinine developed after hospital discharge may have been missed.
Conclusions
In patients with ACS undergoing PCI, blood transfusion is strongly associated with AKI even when it is utilized in Group A: no decrease in hemoglobin or decreased hemoglobin <1 g/dL; group B: decreased hemoglobin 1 to <2 g/dL; group C: decreased hemoglobin 2 to <3 g/dL; group D: hemoglobin decrease ≥ 3 g/dL. AKI indicates acute kidney injury; and OR, odds ratio.
Table 5. Association of Blood Transfusion With Acute Kidney Injury as Stratified by Bleeding and Preprocedure
Hemoglobin Level Blood Transfusion and Acute Kidney Injury anemic patients who subsequently sustained a postprocedure bleeding event. Whether implementing restrictive blood transfusion strategies might improve PCI outcomes by reducing the risk of AKI needs to be further investigated. Severe CKD defined as estimated glomerular filtration rate ≤30 mL/min per 1.73 m 2 . CHF indicates congestive heart failure; CKD, chronic kidney disease; IABP, intra-aortic balloon pump; and OR, odds ratio.
